Insights into the DNA damage response and tumor drug resistance

References

1. 1.↵
   2. Nik-Zainal S,
   3. Davies H,
   4. Staaf J,
   5. Ramakrishna M,
   6. Glodzik D,
   7. Zou X, et al.

   Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature. 2016; 534: 47–54.

   OpenUrlCrossRefPubMed
2. 2.↵
   2. Zhao Y,
   3. Biertümpfel C,
   4. Gregory MT,
   5. Hua YJ,
   6. Hanaoka F,
   7. Yang W.

   Structural basis of human DNA polymerase η-mediated chemoresistance to cisplatin. Proc Natl Acad Sci U S A. 2012; 109: 7269–74.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   2. Lheureux S,
   3. Bruce JP,
   4. Burnier JV,
   5. Karakasis K,
   6. Shaw PA,
   7. Clarke BA, et al.

   Somatic BRCA1/2 recovery as a resistance mechanism after exceptional response to poly (ADP-ribose) polymerase inhibition. J Clin Oncol. 2017; 35: 1240–49.

   OpenUrlCrossRefPubMed
4. 4.↵
   2. Zhang Z,
   3. Liu X,
   4. Li L,
   5. Yang Y,
   6. Yang J,
   7. Wang Y, et al.

   SNP rs4971059 predisposes to breast carcinogenesis and chemoresistance via TRIM46-mediated HDAC1 degradation. EMBO J. 2021; 40: e107974.
5. 5.↵
   2. Ghezraoui H,
   3. Oliveira C,
   4. Becker JR,
   5. Bilham K,
   6. Moralli D,
   7. Anzilotti C, et al.

   53BP1 cooperation with the REV7-shieldin complex underpins DNA structure-specific NHEJ. Nature. 2018; 560: 122–27.

   OpenUrlCrossRefPubMed
6. 6.↵
   2. Chen Y,
   3. Wu J,
   4. Zhai L,
   5. Zhang T,
   6. Yin H,
   7. Gao H, et al.

   Metabolic regulation of homologous recombination repair by MRE11 lactylation. Cell. 2024; 187: 294–311.e21.

   OpenUrlPubMed
7. 7.↵
   2. Chen H,
   3. Li Y,
   4. Li H,
   5. Chen X,
   6. Fu H,
   7. Mao D, et al.

   NBS1 lactylation is required for efficient DNA repair and chemotherapy resistance. Nature. 2024; 631: 663–69.

   OpenUrlCrossRefPubMed
8. 8.↵
   2. Wang YL,
   3. Zhao WW,
   4. Shi J,
   5. Wan XB,
   6. Zheng J,
   7. Fan XJ.

   Liquid-liquid phase separation in DNA double-strand breaks repair. Cell Death Dis. 2023; 14: 746.

   OpenUrlCrossRefPubMed
9. 9.↵
   2. Sanchez-Vega F,
   3. Mina M,
   4. Armenia J,
   5. Chatila WK,
   6. Luna A,
   7. La KC, et al.

   Oncogenic signaling pathways in The Cancer Genome Atlas. Cell. 2018; 173: 321–37.e10.

   OpenUrlCrossRefPubMed
10. 10.↵
    2. Ding X,
    3. Sun F,
    4. Chen J,
    5. Chen L,
    6. Tobin-Miyaji Y,
    7. Xue S, et al.

    Amyloid-forming segment induces aggregation of FUS-LC domain from phase separation modulated by site-specific phosphorylation. J Mol Biol. 2020; 432: 467–83.

    OpenUrlCrossRefPubMed
11. 11.↵
    2. Sanese P,
    3. De Marco K,
    4. Lepore Signorile M,
    5. La Rocca F,
    6. Forte G,
    7. Latrofa M, et al.

    The novel SMYD3 inhibitor EM127 impairs DNA repair response to chemotherapy-induced DNA damage and reverses cancer chemoresistance. J Exp Clin Cancer Res. 2024; 43: 151.

    OpenUrlPubMed
12. 12.↵
    2. Ramakrishnan N,
    3. Weaver TM,
    4. Aubuchon LN,
    5. Woldegerima A,
    6. Just T,
    7. Song K, et al.

    Nucleolytic processing of abasic sites underlies PARP inhibitor hypersensitivity in ALC1-deficient BRCA mutant cancer cells. Nat Commun. 2024; 15: 6343.

    OpenUrlPubMed
13. 13.↵
    2. Zhang FL,
    3. Yang SY,
    4. Liao L,
    5. Zhang TM,
    6. Zhang YL,
    7. Hu SY, et al.

    Dynamic SUMOylation of MORC2 orchestrates chromatin remodelling and DNA repair in response to DNA damage and drives chemoresistance in breast cancer. Theranostics. 2023; 13: 973–90.

    OpenUrlCrossRefPubMed
14. 14.↵
    2. Jacquet K,
    3. Fradet-Turcotte A,
    4. Avvakumov N,
    5. Lambert JP,
    6. Roques C,
    7. Pandita RK, et al.

    The TIP60 complex regulates bivalent chromatin recognition by 53BP1 through direct H4K20me binding and H2AK15 acetylation. Mol Cell. 2016; 62: 409–21.

    OpenUrlCrossRefPubMed
15. 15.↵
    2. Bao K,
    3. Ma Y,
    4. Li Y,
    5. Shen X,
    6. Zhao J,
    7. Tian S, et al.

    A di-acetyl-decorated chromatin signature couples liquid condensation to suppress DNA end synapsis. Mol Cell. 2024; 84: 1206–23.e15.

    OpenUrlPubMed
16. 16.↵
    2. Gulhan DC,
    3. Lee JJ,
    4. Melloni GEM,
    5. Cortés-Ciriano I,
    6. Park PJ.

    Detecting the mutational signature of homologous recombination deficiency in clinical samples. Nat Genet. 2019; 51: 912–19.

    OpenUrlCrossRefPubMed
17. 17.↵
    2. Zhang C,
    3. Zhou B,
    4. Gu F,
    5. Liu H,
    6. Wu H,
    7. Yao F, et al.

    Micropeptide PACMP inhibition elicits synthetic lethal effects by decreasing CtIP and poly(ADP-ribosyl)ation. Mol Cell. 2022; 82: 1297–312.e8.

    OpenUrlCrossRefPubMed
18. 18.↵
    2. Wu W,
    3. Fan Z,
    4. Fu H,
    5. Ma X,
    6. Wang D,
    7. Liu H, et al.

    VGLL3 modulates chemosensitivity through promoting DNA double-strand break repair. Sci Adv. 2024; 10: eadr2643.
19. 19.↵
    2. Konstantinopoulos PA,
    3. Cheng SC,
    4. Wahner Hendrickson AE,
    5. Penson RT,
    6. Schumer ST,
    7. Doyle LA, et al.

    Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2020; 21: 957–68.

    OpenUrlPubMed
20. 20.↵
    2. Gallo D,
    3. Young JTF,
    4. Fourtounis J,
    5. Martino G,
    6. Álvarez-Quilón A,
    7. Bernier C, et al.

    CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition. Nature. 2022; 604: 749–56.

    OpenUrlCrossRefPubMed
21. 21.↵
    2. Ma X,
    3. Yang F,
    4. Ma K,
    5. Shen H,
    6. Han J,
    7. Wang K, et al.

    Ganoboninketal C from Ganoderma boninense improves the efficacy of CDDP-based chemotherapy through inhibiting translesion DNA synthesis. Food Sci Hum Wellness. 2024; 13: 2982–92.

    OpenUrl